Pharmacoeconomics in Healthcare

Rai, Mahendra; Goyal, Richa

doi:10.1016/b978-0-12-802103-3.00034-1

Cited by 29 publications

(19 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Economic costs match the broader concept of resource consumption, irrespective of whether such resources are traded in the market. 13 , 24 In Table 2 , we summarize and specify the types of costs that are considered in pharmacoeconomics. These costs together with the expected pharmacoeconomic efficacy measure when applying nanocarriers in cancer treatment are shown in Table 3 .…”

Section: Pharmacoeconomics – a Use Case Of Nanocarriers Evaluationmentioning

confidence: 99%

Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment

Milewska¹,

Niemirowicz-Laskowska²,

Siemiaszko³

et al. 2021

IJN

View full text Add to dashboard Cite

Nanotherapy is a part of nanomedicine that involves nanoparticles as carriers to deliver drugs to target locations. This novel targeting approach has been found to resolve various problems, especially those associated with cancer treatment. In nanotherapy, the carrier plays a crucial role in handling many of the existing challenges, including drug protection before early-stage degradations of active substances, allowing them to reach targeted cells and overcome cell resistance mechanisms. The present review comprises the following sections: the first part presents the introduction of pharmacoeconomics as a branch of healthcare economics, the second part covers various beneficial aspects of the use of nanocarriers for in vitro, in vivo, and pre- and clinical studies, as well as discussion on drug resistance problem and present solutions to overcome it. In the third part, progress in drug manufacturing and optimization of the process of nanoparticle synthesis were discussed. Finally, pharmacokinetic and toxicological properties of nanoformulations due to up-to-date studies were summarized. In this review, the most recent developments in the field of nanotechnology’s economic impact, particularly beneficial applications in medicine were presented. Primarily focus on cancer treatment, but also discussion on other fields of application, which are strongly associated with cancer epidemiology and treatment, was made. In addition, the current limitations of nanomedicine and its huge potential to improve and develop the health care system were presented.

show abstract

Section: Pharmacoeconomics – a Use Case Of Nanocarriers Evaluationmentioning

confidence: 99%

Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment

Milewska¹,

Niemirowicz-Laskowska²,

Siemiaszko³

et al. 2021

IJN

View full text Add to dashboard Cite

show abstract

“…Thus, our use of the cost minimization model was valid, as our results indicated that the effectiveness of treatment with either EC or PMMA were equivalent between treatments. Cost minimization analysis is only valid when this condition is met; otherwise, cost-effectiveness or costutility analyses must be performed (11,12). There are of course institutional differences in the contracted cost of EC implants, and in the cost of OR time.…”

Section: Discussionmentioning

confidence: 99%

Outcomes and cost-minimization analysis of cement spacers versus expandable cages for posterior-only reconstruction of metastatic spine corpectomies

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Thus, the ICUR gives the cost per additional QALY gained as a result of the management option over its comparator. 3 It should be noted that many studies use the terms ICUR and ICER (incremental cost-effectiveness ratio) interchangeably.…”

Section: Measuring Health Utility and Incremental Cost-utility Ratiomentioning

confidence: 99%

Understanding cost-utility analysis studies in the trauma and orthopaedic surgery literature

et al. 2021

View full text Add to dashboard Cite

Cost-utility analysis (CUA) studies are becoming increasingly important due to the need to reduce healthcare spending, especially in the field of trauma and orthopaedics. There is an increasing need for trauma and orthopaedic surgeons to understand these economic evaluations to ensure informed cost-effective decisions can be made to benefit the patient and funding body. This review discusses the fundamental principles required to understand CUA studies in the literature, including a discussion of the different methods employed to assess the health outcomes associated with different management options and the various approaches used to calculate the costs involved. Different types of model design may be used to conduct a CUA which can be broadly categorized into real-life clinical studies and computer-simulated modelling. We discuss the main types of study designs used within each category. We also cover the different types of sensitivity analysis used to quantify uncertainty in these studies and the commonly employed instruments used to assess the quality of CUAs. Finally, we discuss some of the important limitations of CUAs that need to be considered. This review outlines the main concepts required to understand the CUA literature and provides a basic framework for their future conduct. Cite this article: EFORT Open Rev 2021;6:305-315. DOI: 10.1302/2058-5241.6.200115

show abstract

Pharmacoeconomics in Healthcare

Cited by 29 publications

References 3 publications

Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment

Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment

Outcomes and cost-minimization analysis of cement spacers versus expandable cages for posterior-only reconstruction of metastatic spine corpectomies

Understanding cost-utility analysis studies in the trauma and orthopaedic surgery literature

Contact Info

Product

Resources

About